

**Amendment to Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-5. (Canceled).

6-7. (Withdrawn).

8-12. (Canceled).

13-14. (Withdrawn).

15. (Canceled).

16. (Currently Amended) An orally administrable immediate release fenofibrate tablet, wherein the required daily dose is lower than 200mg, and wherein the bioavailability is greater than that of Lipanthyl®200M (co-micronized fenofibrate).

17. (Canceled).

18. (Original) The tablet of claim 16, wherein the fenofibrate is present in an amount of 5 to 50% by weight.

19. (Original) The tablet of claim 16, wherein the fenofibrate is present in an amount of 20 to 45% by weight.

20. (Original) The tablet of claim 16 which is once-daily.

21-24. (Canceled).

25-33. (Withdrawn).

34-35. (Canceled).

36. (Original) The tablet according to claim 16, wherein the fenofibrate is in a non-reagglomerated form.

37. (Canceled).

38-39. (Withdrawn).

40. (Canceled).

41. (New) The tablet according to claim 16, wherein the bioavailability is assessed by AUC,  $C_{\max}$  or both.

42. (New) An orally administrable immediate release fenofibrate tablet, wherein the required daily dose is lower than 200mg, and wherein the bioavailability is greater than that of Lipanthyl®200M (co-micronized fenofibrate), the bioavailability being assessed by AUC,  $C_{\max}$  or both.

43. (New) The tablet of claim 42 which is once-daily.

44. (New) The tablet of claim 42, wherein the fenofibrate is present in an amount of 5 to 50% by weight.

45. (New) The tablet of claim 42, wherein the fenofibrate is present in an amount of 20 to 45% by weight.

46. (New) An orally administrable once-daily immediate release fenofibrate tablet, wherein the required daily dose is lower than 200mg, and wherein the bioavailability is greater than that of Lipanthyl®200M (co-micronized fenofibrate), the bioavailability being assessed by AUC and  $C_{\max}$ .

47. (New) The tablet of claim 46, wherein the fenofibrate is present in an amount of 5 to 50% by weight.

48. (New) The tablet of claim 46, wherein the fenofibrate is present in an amount of 20 to 45% by weight.